This is a best-case-scenario data readout that significantly de-risks the sBLA submission for full approval in Q4 2026. The combination of unprecedented efficacy (eGFR stabilization, 76% risk reduction) and a clean safety profile positions TRUTAKNA as a potential standard-of-care in IgAN. Traders should expect a strong positive reaction and monitor for analyst upgrades and increased institutional interest. The strong commercial launch metrics (350+ patient start forms in 10 weeks) provide additional near-term revenue visibility.
Drug in focus
VERA drug pipeline →TRUTAKNA
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Next catalyst
- None dated
What to watchThe FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $33.67entry
- T+1 · 2mo ago −6.33%α −6.65% · $31.54
- T+5 · 8w ago +0.98%α +0.16% · $34.00
- T+20 · 5w ago −20.43%α −23.41% · $26.79
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial in IgA nephropathy (IgAN). The drug demonstrated a 5.6 mL/min/1.73m2 placebo-adjusted difference in mean eGFR change at 52 weeks (p<0.0001), a 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, p<0.0001), and a favorable safety profile. The company plans to submit a supplemental BLA for full approval in Q4 2026, and reported strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. This is a transformative data readout that strongly supports the drug's disease-modifying potential and de-risks the path to full approval, representing a major positive catalyst for the stock.
Key Facts
- TRUTAKNA met all prespecified endpoints in the ORIGIN 3 final efficacy analysis (n=428).
- Placebo-adjusted difference in mean eGFR change from baseline at 52 weeks was 5.6 mL/min/1.73m2 (p<0.0001).
- Annualized eGFR slope through 104 weeks showed a placebo-adjusted difference of 5.0 mL/min/1.73m2/year (p<0.0001).
- 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, 95% CI 0.12-0.48, p<0.0001).
- Zero dialysis, transplant, or death events in the TRUTAKNA arm vs. 8 in placebo through 104 weeks.
- Company plans to submit supplemental BLA for full approval in Q4 2026.
- Over 350 patient start forms generated in the first ten weeks of commercial launch.
- Cash, cash equivalents, and marketable securities of ~$499M as of June 30, 2026, with additional $425M non-dilutive capital available through Oxford Facility.
Financial Impact
Transformative data supports full approval pathway for TRUTAKNA in IgAN, a potential $10B+ U.S. market opportunity. The 76% risk reduction in kidney disease progression and stabilization of eGFR at physiologic rates are best-in-class results that could drive significant market share and peak sales.
Risk Factors
- Full FDA approval is not guaranteed and depends on the sBLA review process in 2027.
- Competition from other IgAN therapies (e.g., sparsentan, iptacopan, other BAFF/APRIL inhibitors) could limit market share.
- Commercial execution risk remains as the launch scales, including payer coverage and physician adoption.
- The $425M Oxford Facility is subject to conditions and may not be fully accessible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391280 |
| Document: d32300d8k.htm | 0001193125-26-391280 |
| Document: d32300dex991.htm | 0001193125-26-391280 |
| Document: 0001193125-26-391280-index-headers.html | 0001193125-26-391280 |
| Document: 0001193125-26-391280-index.html | 0001193125-26-391280 |
| Document: 0001193125-26-391280.txt | 0001193125-26-391280 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Viewing Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers